Search results for "Neoplasias Colorrectais"

showing 2 items of 2 documents

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR…

2017

BACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour location (side), might be both prognostic and predictive for clinical outcome. METHODS: This retrospective analysis investigated the prognostic and predictive influence of the localization of the primary tumour in patients with unresectable RAS wt mCRC included in six randomized trials (CRY…

Male0301 basic medicineOncologyColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeEGFR Antibody0302 clinical medicineAntineoplastic Agents ImmunologicalNeoplasias ColorrectaisMedicineNeoplasm MetastasisRandomized Controlled Trials as Topicpredictive valuePanitumumabHazard ratiotumour sideAntibodies MonoclonalHematologyPrognosisChemotherapy regimenErbB ReceptorsBevacizumabTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyBevacizumabcolorectal cancerGenes ras03 medical and health sciencesAnticorpos MonoclonaisInternal medicineHumansChemotherapybusiness.industryAntineoplásicos ImunológicosOdds ratiomedicine.diseaserandomised trial030104 developmental biologyGenes rasHuman medicinebusinessprognosticanti-EGFR treatment
researchProduct